Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules

Area of Science:

• Neuroscience
• Clinical Neurology
• Rehabilitation Medicine

Background:

• The Multiple Sclerosis Performance Test (MSPT) is a patient self-administered tool for assessing neuroperformance in individuals with multiple sclerosis (MS).
• Existing assessments may not fully capture the nuances of MS-related functional decline.
• Objective and reliable metrics are needed for clinical practice and outcomes research in MS.

Purpose of the Study:

• To determine the test-retest reliability, practice effects, convergent validity, and sensitivity to MS disability of MSPT neuroperformance subtests.
• To evaluate the Contrast Sensitivity Test (CST), Manual Dexterity Test (MDT), and Walking Speed Test (WST).
• To introduce regression-based norms for interpreting the MSPT cognition test (Processing Speed Test, PST).

Main Methods:

• Substudy 1: Assessed reliability and validity of CST, MDT, WST in 30 MS patients and 30 controls.
• Substudy 2: Examined sensitivity to MS disability in over 600 MS patients.
• Substudy 3: Compared PST performance between research volunteers and clinical samples.

Main Results:

• The CST, MDT, and WST demonstrated reliability, validity, and sensitivity to MS outcomes.
• Self-administered MSPT performance was comparable to technician-administered tests.
• The Processing Speed Test (PST) showed poorer performance in a clinical sample versus a research sample.

Conclusions:

• Self-administered MSPT neuroperformance modules yield reliable, objective metrics for clinical practice and MS outcomes research.
• These tools enhance the objective assessment of neurological function in MS.
• Cognitive dysfunction may be underestimated in studies relying solely on voluntary consent, highlighting the value of clinical sample data.